<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03581409</url>
  </required_header>
  <id_info>
    <org_study_id>B-1712/439-001</org_study_id>
    <nct_id>NCT03581409</nct_id>
  </id_info>
  <brief_title>Comparison of Two Different Antiplatelet Preparations for an Unruptured Intracranial Aneurysm</brief_title>
  <official_title>Comparison of Dual-Antiplatelet and Triple-Antiplatelet Preparation Using P2Y12 Assay in Patients With High On-Treatment Platelet Reactivity Undergoing Stent-Assisted Coil Embolization for An Unruptured Intracranial Aneurysm</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Perform a randomized comparison study of dual-antiplatelet (aspirin, prasugrel) and
      triple-antiplatelet (aspirin, clopidogrel, and cilostazol) preparation using P2Y12 assay in
      patients with high on-treatment platelet reactivity undergoing stent-assisted coil
      embolization for an unruptured intracranial aneurysm
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comparison between dual-antiplatelet and triple-platelet preparation
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 24, 2018</start_date>
  <completion_date type="Anticipated">December 11, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 11, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of hemorrhagic complications between 2 arms</measure>
    <time_frame>through study completion (for 3 months)</time_frame>
    <description>check minor and major hemorrhagic complications after procedures</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of the level of P2Y12</measure>
    <time_frame>through study completion (for 3 months)</time_frame>
    <description>Check the change of the level of P2Y12 according to each arms during study periods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of thromboembolic complications between 2 arms</measure>
    <time_frame>through study completion (for 3 months)</time_frame>
    <description>check minor and major thromboembolic complications after procedures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality between 2 arms</measure>
    <time_frame>through study completion (for 3 months)</time_frame>
    <description>check mortality after procedures</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">176</enrollment>
  <condition>Aneurysm, Cerebral</condition>
  <condition>Endovascular Procedures</condition>
  <arm_group>
    <arm_group_label>dual-antiplatelet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with unruptured aneurysms received dual antiplatelet agents (100 mg of aspirin and 75 mg of clopidogrel) for at least five days before embolization. One day prior to coil embolization, P2Y12 reaction units were measured using VerifyNow. Patients with clopidogrel resistance (greater than 220 PRU) received prasugrel 20mg. After that, dual-antiplatelet (aspirin 100mg &amp; prasugrel 5mg) treatment continued for 3 months through study completion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>triple-antiplatelet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with unruptured aneurysms received dual antiplatelet agents (100 mg of aspirin and 75 mg of clopidogrel) for at least five days before embolization. One day prior to coil embolization, P2Y12 reaction units (PRU) were measured using VerifyNow. Patients with clopidogrel resistance (greater than 220 PRU) received cilostazol 200mg. After that, triple-antiplatelet (aspirin 100mg, clopidogrel 75mg, and cilostazol 200mg) treatment continued for 3 months through study completion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Aspirin protect tablet</description>
    <arm_group_label>dual-antiplatelet</arm_group_label>
    <arm_group_label>triple-antiplatelet</arm_group_label>
    <other_name>Aspirin protect</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel</intervention_name>
    <description>Prasugrel tablet</description>
    <arm_group_label>dual-antiplatelet</arm_group_label>
    <other_name>Effient</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Clopidogrel 75mg tablet</description>
    <arm_group_label>triple-antiplatelet</arm_group_label>
    <other_name>Plavix</other_name>
    <other_name>Plavitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilostazol</intervention_name>
    <description>Cilostazol tablet</description>
    <arm_group_label>triple-antiplatelet</arm_group_label>
    <other_name>Pletaal</other_name>
    <other_name>Cilostan CR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with clopidogrel resistance (greater than 220 P2Y12 reaction units using
             VerifyNow)

          -  patients with unruptured intracranial aneurysms

          -  patients over 20 years old

          -  patients who can communicate with each other

          -  patients who agreed to this study (with informed consent)

        Exclusion Criteria:

          -  patients with recurrent aneurysms after coiling or clipping

          -  patients with allergic reaction to antiplatelets

          -  patients with high risks of hemorrhage

          -  patients with coagulopathy

          -  patients with thrombocytopenia (&lt;100,000/mm3)

          -  patients with liver disease (&gt; 100 of aspartate aminotransferase or alanine
             aminotransferase)

          -  patients with renal disease (&gt; 2mg/dL of serum creatinine)

          -  patients with uncontrolled heart failure or angina

          -  patients with malignant tumor

          -  pregnant patients

          -  patients with past history that may associated with headache, including subarachnoid
             hemorrhage, head trauma, intracerebral hemorrhage, trigeminal neuralgia, arteriovenous
             malformation, brain tumor)

          -  Patients who are determined to be disqualified by researchers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seung Pil Ban, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National Bundang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seung Pil Ban, M.D.</last_name>
    <phone>82-31-787-7175</phone>
    <email>neurosurgeryban@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>O-Ki Kwon, M.D., Ph.D.</last_name>
    <phone>82-31-787-7163</phone>
    <email>meurokwonoki@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National Univeristy Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung Pil Ban, M.D.</last_name>
      <phone>82-31-787-7175</phone>
      <email>neurosurgeryban@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>O-Ki Kwon, M.D., Ph.D.</last_name>
      <phone>82-31-787-7163</phone>
      <email>meurokwonoki@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Tackeun Kim, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Geyik S, Yavuz K, Yurttutan N, Saatci I, Cekirge HS. Stent-assisted coiling in endovascular treatment of 500 consecutive cerebral aneurysms with long-term follow-up. AJNR Am J Neuroradiol. 2013 Nov-Dec;34(11):2157-62. doi: 10.3174/ajnr.A3574. Epub 2013 Jul 25.</citation>
    <PMID>23886748</PMID>
  </results_reference>
  <results_reference>
    <citation>Hwang G, Huh W, Lee JS, Villavicencio JB, Villamor RB Jr, Ahn SY, Kim J, Chang JY, Park SJ, Park NM, Jeong EA, Kwon OK. Standard vs Modified Antiplatelet Preparation for Preventing Thromboembolic Events in Patients With High On-Treatment Platelet Reactivity Undergoing Coil Embolization for an Unruptured Intracranial Aneurysm: A Randomized Clinical Trial. JAMA Neurol. 2015 Jul;72(7):764-72. doi: 10.1001/jamaneurol.2015.0654.</citation>
    <PMID>26010803</PMID>
  </results_reference>
  <results_reference>
    <citation>Park KH, Jeong MH, Lee KH, Sim DS, Yoon HJ, Yoon NS, Kim KH, Park HW, Hong YJ, Kim JH, Ahn Y, Cho JG, Park JC, Kang JC. Comparison of peri-procedural platelet inhibition with prasugrel versus adjunctive cilostazol to dual anti-platelet therapy in patients with ST segment elevation myocardial infarction. J Cardiol. 2014 Feb;63(2):99-105. doi: 10.1016/j.jjcc.2013.07.004. Epub 2013 Sep 5.</citation>
    <PMID>24012432</PMID>
  </results_reference>
  <results_reference>
    <citation>Hwang G, Kim JG, Song KS, Lee YJ, Villavicencio JB, Suroto NS, Park NM, Park SJ, Jeong EA, Kwon OK. Delayed ischemic stroke after stent-assisted coil placement in cerebral aneurysm: characteristics and optimal duration of preventative dual antiplatelet therapy. Radiology. 2014 Oct;273(1):194-201. doi: 10.1148/radiol.14140070. Epub 2014 Jun 11.</citation>
    <PMID>24918960</PMID>
  </results_reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>June 14, 2018</study_first_submitted>
  <study_first_submitted_qc>July 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2018</study_first_posted>
  <last_update_submitted>October 9, 2019</last_update_submitted>
  <last_update_submitted_qc>October 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>antiplatelet preparation</keyword>
  <keyword>cerebral aneurysm</keyword>
  <keyword>coil embolization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Aneurysm</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Cilostazol</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

